A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation.

[1]  R. Laing,et al.  Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). , 2015, European urology.

[2]  J. Fütterer,et al.  Preferences in the management of high‐risk prostate cancer among urologists in Europe: results of a web‐based survey , 2015, BJU international.

[3]  Michael Kerger,et al.  Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer , 2015, Nature Communications.

[4]  M. Nykter,et al.  The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.

[5]  D. Pfister,et al.  Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. , 2015, The Journal of urology.

[6]  C. Stief,et al.  Role of Radical Prostatectomy in Clinically Non-Organ-Confined Prostate Cancer , 2014, Current Urology Reports.

[7]  C. Stief,et al.  Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. , 2014, European urology.

[8]  S. Boorjian,et al.  The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. , 2014, European urology.

[9]  P. Schellhammer,et al.  Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. , 2014, European urology.

[10]  S. McGuire,et al.  Is treatment of the primary tumor in metastatic prostate cancer justified? , 2014, European urology.

[11]  R. DiPaola,et al.  Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Wiklund,et al.  Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes , 2014, BMJ : British Medical Journal.

[13]  Ashutosh Tewari,et al.  Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. , 2012, European urology.

[14]  A. Jemal,et al.  International variation in prostate cancer incidence and mortality rates. , 2012, European urology.

[15]  J. Steffens,et al.  A single center prospective study: prediction of postoperative general quality of life, potency and continence after radical retropubic prostatectomy. , 2011, The Journal of urology.

[16]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[17]  Bethan Psaila,et al.  The metastatic niche: adapting the foreign soil , 2009, Nature Reviews Cancer.

[18]  U. Roggenbuck,et al.  Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006. , 2008, The Journal of urology.

[19]  P. Scardino,et al.  The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. , 2007, European urology.

[20]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[21]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[22]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[23]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[24]  Wim Ceelen,et al.  Surgery, wound healing, and metastasis: recent insights and clinical implications. , 2014, Critical reviews in oncology/hematology.

[25]  T. H. van der Kwast,et al.  [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. , 2011, Actas urologicas espanolas.

[26]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.